# Safety and Efficacy Study of Isolagen TherapyTM in Treatment of Interdental Papillary Insufficiency

> **NCT00655889** · PHASE2 · COMPLETED · sponsor: **Castle Creek Biosciences, LLC.** · enrollment: 13 (actual)

## Conditions studied

- Interdental Papillary Insufficiency

## Interventions

- **BIOLOGICAL:** Autologous Human Fibroblasts (azficel-T)

## Key facts

- **NCT ID:** NCT00655889
- **Lead sponsor:** Castle Creek Biosciences, LLC.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2008-04
- **Final completion:** 2008-07
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2021-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00655889

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00655889, "Safety and Efficacy Study of Isolagen TherapyTM in Treatment of Interdental Papillary Insufficiency". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00655889. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*